Cantor Fitzgerald Reiterates Overweight on Intellia Therapeutics, Maintains $65 Price Target
Intellia Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $54
Qiagen Analyst Ratings
Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target
CRISPR Therapeutics Analyst Ratings
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating
Bank rating: O'Brienheimer raised the target price of Moderna to $179, indicating that its RSV vaccine still has ample opportunities.
Avidity Biosciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45
Chardan Raises Price Target on Avidity Biosciences to $45 From $33, Maintains Buy Rating
Moderna Analyst Ratings
Oppenheimer Raises Price Target on Moderna to $179 From $163
Arrowhead Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
Avidity Biosciences Analyst Ratings
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Jefferies Adjusts Price Target on Moderna to $180 From $155, Keeps Buy Rating
Arrowhead Pharma Analyst Ratings